Postoperative adjuvant EGFR-TKIs for resected -mutant NSCLC-opportunities and obstacles.
作者信息
Parris Brielle A, Leong Steven, Marshall Henry, Yang Ian A, Bowman Rayleen V, Fong Kwun M
机构信息
University of Queensland Thoracic Research Centre at The Prince Charles Hospital, Brisbane, Australia.
Department of Thoracic Medicine, The Prince Charles Hospital, Brisbane, Australia.
出版信息
Ann Transl Med. 2021 Apr;9(7):586. doi: 10.21037/atm-2020-133.
Abstract
摘要
相似文献
1
Postoperative adjuvant EGFR-TKIs for resected -mutant NSCLC-opportunities and obstacles.用于可切除的EGFR突变型非小细胞肺癌的术后辅助表皮生长因子受体酪氨酸激酶抑制剂——机遇与障碍
Ann Transl Med. 2021 Apr;9(7):586. doi: 10.21037/atm-2020-133.
2
EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.表皮生长因子受体抑制剂作为表皮生长因子受体突变的可切除非小细胞肺癌的辅助治疗。
Lung Cancer. 2019 Oct;136:6-14. doi: 10.1016/j.lungcan.2019.08.001. Epub 2019 Aug 2.
3
Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials.辅助 EGFR-TKIs 治疗可切除非小细胞肺癌的疗效和安全性：基于随机对照试验的系统评价和荟萃分析。
BMC Cancer. 2022 Mar 26;22(1):328. doi: 10.1186/s12885-022-09444-0.
4
Adjuvant EGFR-TKIs for Patients With Resected EGFR-Mutant Non-Small Cell Lung Cancer: A Meta-Analysis of 1,283 Patients.表皮生长因子受体酪氨酸激酶抑制剂辅助治疗可切除的表皮生长因子受体突变非小细胞肺癌患者：1283例患者的荟萃分析
Front Oncol. 2021 Apr 12;11:629394. doi: 10.3389/fonc.2021.629394. eCollection 2021.
5
A meta-analysis of adjuvant EGFR-TKIs for patients with resected non-small cell lung cancer.辅助 EGFR-TKIs 治疗可切除非小细胞肺癌的荟萃分析。
Lung Cancer. 2019 Nov;137:7-13. doi: 10.1016/j.lungcan.2019.08.002. Epub 2019 Aug 5.
6
Rational application of EGFR-TKI adjuvant therapy in patients with completely resected stage IB-IIIA EGFR-mutant NSCLC: a systematic review and meta-analysis of 11 randomized controlled trials.完全切除的 IB 期-IIIA 期 EGFR 突变型 NSCLC 患者中表皮生长因子受体酪氨酸激酶抑制剂辅助治疗的合理应用：11 项随机对照试验的系统评价和荟萃分析。
BMC Cancer. 2023 Aug 1;23(1):719. doi: 10.1186/s12885-023-11194-6.
7
Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Adjuvant Setting for Patients with Resected Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer: A Meta-Analysis with 11 Trials.表皮生长因子受体酪氨酸激酶抑制剂在表皮生长因子受体突变型非小细胞肺癌切除术后辅助治疗中的疗效：一项包含 11 项试验的荟萃分析。
Oncol Res Treat. 2021;44(6):344-353. doi: 10.1159/000515230. Epub 2021 May 5.
8
PD-L1 expression and its effect on clinical outcomes of EGFR-mutant NSCLC patients treated with EGFR-TKIs.PD-L1表达及其对接受EGFR-TKI治疗的EGFR突变型非小细胞肺癌患者临床结局的影响。
Cancer Biol Med. 2018 Nov;15(4):434-442. doi: 10.20892/j.issn.2095-3941.2018.0223.
9
Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations.第一代表皮生长因子受体酪氨酸激酶抑制剂（吉非替尼、厄洛替尼和埃克替尼）作为可切除的、具有敏感表皮生长因子受体突变的非小细胞肺癌患者辅助治疗的比较。
Transl Lung Cancer Res. 2021 Nov;10(11):4120-4129. doi: 10.21037/tlcr-21-649.
10
Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC.奥希替尼：完全切除的、早期、EGFR 突变阳性 NSCLC 中的研究。
Target Oncol. 2022 May;17(3):369-376. doi: 10.1007/s11523-022-00883-0. Epub 2022 Jun 17.
本文引用的文献
1
Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition).转化医学学会关于表皮生长因子受体（EGFR）突变型肺癌术后管理的共识（2019年版）
Transl Lung Cancer Res. 2019 Dec;8(6):1163-1173. doi: 10.21037/tlcr.2019.12.14.
2
Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 -Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study.厄洛替尼对比吉西他滨联合顺铂用于 IIIA-N2 期突变型非小细胞肺癌的新辅助治疗（EMERGING-CTONG 1103）：一项随机 II 期研究。
J Clin Oncol. 2019 Sep 1;37(25):2235-2245. doi: 10.1200/JCO.19.00075. Epub 2019 Jun 13.
3
Differential effects of adjuvant EGFR tyrosine kinase inhibitors in patients with different stages of non-small-cell lung cancer after radical resection: an updated meta-analysis.辅助性表皮生长因子受体酪氨酸激酶抑制剂对非小细胞肺癌根治术后不同分期患者的差异效应：一项更新的荟萃分析。
Cancer Manag Res. 2019 Apr 2;11:2677-2690. doi: 10.2147/CMAR.S187940. eCollection 2019.
4
A Nomogram for Predicting Cancer-Specific Survival of TNM 8th Edition Stage I Non-small-cell Lung Cancer.第八版 TNM 分期Ⅰ期非小细胞肺癌患者癌症特异性生存的列线图预测模型。
Ann Surg Oncol. 2019 Jul;26(7):2053-2062. doi: 10.1245/s10434-019-07318-7. Epub 2019 Mar 21.
5
Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial.厄洛替尼对比长春瑞滨联合顺铂用于表皮生长因子受体突变阳性的 IIIA 期非小细胞肺癌中国患者的辅助治疗（EVAN）：一项随机、开放标签、二期临床试验。
Lancet Respir Med. 2018 Nov;6(11):863-873. doi: 10.1016/S2213-2600(18)30277-7. Epub 2018 Aug 24.
6
The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.切除的非小细胞肺癌中单种和多种癌症相关体细胞突变的预后影响。
Lung Cancer. 2018 Sep;123:22-29. doi: 10.1016/j.lungcan.2018.06.023. Epub 2018 Jun 19.
7
ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection.ADAURA：奥希替尼对比安慰剂用于完全手术切除后的 EGFR 突变阳性早期 NSCLC 患者的 III 期、双盲、随机研究。
Clin Lung Cancer. 2018 Jul;19(4):e533-e536. doi: 10.1016/j.cllc.2018.04.004. Epub 2018 May 1.
8
Gefitinib for advanced non-small cell lung cancer.吉非替尼用于治疗晚期非小细胞肺癌。
Cochrane Database Syst Rev. 2018 Jan 16;1(1):CD006847. doi: 10.1002/14651858.CD006847.pub2.
9
Gastrointestinal Stromal Tumors.胃肠道间质瘤。
J Clin Oncol. 2018 Jan 10;36(2):136-143. doi: 10.1200/JCO.2017.74.9705. Epub 2017 Dec 8.
10
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.吉非替尼对比长春瑞滨联合顺铂作为 EGFR 突变型 II-IIIA 期（N1-N2）可切除 NSCLC（ADJUVANT/CTONG1104）的辅助治疗：一项随机、开放标签、III 期研究。
Lancet Oncol. 2018 Jan;19(1):139-148. doi: 10.1016/S1470-2045(17)30729-5. Epub 2017 Nov 21.
Zotero 插件